Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort.

Courtney N NicholsMark LustbergMohammed Mahdee E SobhanieLucia J NiermannMelissa GordonNicholas KmanJonathan ParsonsMark ConroyMichael DickJames AllenErica ReedJoy LehmanCarlos Malvestutto

Published in: Antiviral therapy (2024)

Individuals treated with MAT had lower rates of 30-day COVID-19-related ED visits and hospital admissions compared to those not receiving MAT. Early MAT resulted in lower 30-day mortality compared to receipt >2 days post COVID-19 diagnosis.

Keyphrases

coronavirus disease
monoclonal antibody
sars cov
respiratory syndrome coronavirus
emergency department
cardiovascular events
newly diagnosed
type diabetes
cardiovascular disease
mesenchymal stem cells
replacement therapy